

## Record medicinal cannabis purchase orders achieved in Q1 FY2021


- Purchase orders for 2,630 MediCabilis™ units received during Q1 FY2021 – a 165% increase on the prior quarter
- 1,630 units delivered from existing purchase orders in Q1 FY2021 – marking over 41% of prescription volumes generated in FY2020 (FY2020 prescriptions: ~4,000)
- Remaining units to be dispensed and invoiced during current quarter (Q2 FY2021)
- Record growth driven by strong product uptake in Australia and clinical trial initiatives
- Additional sales expected from ongoing scale up of UK operations and participation in Europe’s largest medicinal cannabis registry, Project Twenty21

**Sydney, Australia – 7 October 2020:** Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (“Bod”, or “the Company”) (ASX: BDA) is pleased to report that it has achieved record medicinal cannabis growth during Q1 FY2021, receiving purchase orders for a total of 2,630 MediCabilis™ units – highlighting 165% quarter on quarter uplift (Q4 FY2020 prescriptions: 989).

The Company has delivered approximately 1,630 units which will be reflected as sales for the quarter, with the balance to be shipped to partner clinics during Q2 FY2021. The delivery of the initial 1,630 units equates to over 41% of the total MediCabilis™ prescriptions filled during FY2020 (FY2020 prescriptions: ~4,000).

Growth in prescription volumes is attributed to continued product uptake and strong brand recognition in Australia, as well as the Company’s nationwide clinical observational study (refer ASX announcement: 16 July 2020). Bod has also continued to progress educational initiatives with Australian prescribers, which assisted in generating additional sales.

The Company anticipates that it will achieve continued sales growth during Q2, particularly as operations in the UK continue to scale. Bod recently entered into a strategic agreement with LYPHE Group in the UK (refer ASX announcement: 1 September 2020), which will drive growth through the region. Bod’s participation in Europe’s largest medicinal cannabis registry, Project Twenty21 (refer ASX announcement: 11 May 2020) is also expected to support prescription volumes.



**Image one:** cumulative units sold on a month-by-month basis (excluding unfilled purchase orders)

**CEO Jo Patterson said:** “Receiving these purchase orders for our Medicinal Cannabis product, MediCabilis™ range, is a great achievement for Bod and we are very pleased with the ongoing increase in sales. Bod has achieved market leading brand recognition in Australia through clinical trial and educational initiatives, which has directly assisted growth.

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

### CAPITAL STRUCTURE

ASX code **BDA**  
 Shares on issue 91.4m  
 Market Capitalisation ~\$33.3m

### BOARD & MANAGEMENT

Mr Mark Masterson  
 Non-Executive Chairman

Ms Jo Patterson  
 Chief Executive Officer

Mr Akash Bedi  
 Non-Executive Director

Mr George Livery  
 Non-Executive Director

Mr Patrice Malard  
 Non-Executive Director

Mr Simon O’Loughlin  
 Non-Executive Director

Mr Stephen Kelly  
 Company Secretary

### CONTACT

Level 1, 377 New South Head Rd  
 Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

*“As Project Twenty21 and our agreement with LYPHE Group in the UK scale up, we are confident that prescription volumes will follow. Sales are anticipated to continue in Australia, particularly as MediCabilis™ and cannabis more broadly becomes a standard treatment for a number of debilitating conditions such as chronic pain, insomnia, Post Traumatic Stress and anxiety.*

*“We continue to witness strong demand for our MediCabilis™ product range through new and repeat patients and I look forward to providing regular updates on product uptake in the coming months.”*

- ENDS -

## ABOUT BOD AUSTRALIA

**Bod Australia Limited (ASX:BDA)** Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

**This announcement was authorised for release by the Board of Directors of Bod Australia Limited.**

**For more information please contact:**

Jo Patterson  
Chief Executive Officer  
[info@bodaustralia.com](mailto:info@bodaustralia.com)  
+61 2 9199 5018

Henry Jordan  
Six Degrees Investor Relations  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
+61 431 271 538